Amneal submits abbreviated new drug applications to u.s. fda for three key complex generics

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced it has submitted abbreviated new drug applications (“anda”) to the u.s. food and drug administration (fda) for three key complex generic products, including:     product dosage category u.s. iqvia sales (ttm may 2023) 1   albuterol sulfate inhalation inhalation $814 million 2   bimatoprost ophthalmic solution, 0.01% ophthalmic $779 million 3   propofol emulsion injectable $3.
AMRX Ratings Summary
AMRX Quant Ranking